On the public citation graph

The human microbiome and genitourinary malignancies

https://doi.org/10.21037/atm-20-2976
0 signed · 103 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2017.2411openalex-snapshot
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
inferredcites →https://doi.org/10.1002/1097-0142(19811215)48:12<2643::aid-cncr2820481216>3.0.co;2-copenalex-snapshot
The impact of schistosomiasis on the pathology of bladder carcinoma
inferredcites →https://doi.org/10.1002/pros.23713openalex-snapshot
A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis
inferredcites →https://doi.org/10.1007/s00520-014-2487-6openalex-snapshot
Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model
inferredcites →https://doi.org/10.1016/0027-5107(94)90248-8openalex-snapshot
Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients
inferredcites →https://doi.org/10.1016/j.clgc.2018.05.001openalex-snapshot
Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1016/j.euo.2019.09.001openalex-snapshot
Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
inferredcites →https://doi.org/10.1016/j.eururo.2018.06.033openalex-snapshot
Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer
inferredcites →https://doi.org/10.1016/j.juro.2017.08.001openalex-snapshot
Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer
inferredcites →https://doi.org/10.1016/j.urology.2017.08.039openalex-snapshot
The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study
inferredcites →https://doi.org/10.1016/j.urolonc.2007.08.008openalex-snapshot
1. Sorafenib in advanced clear-cell renal-cell carcinoma
inferredcites →https://doi.org/10.1016/s0084-3873(08)79179-xopenalex-snapshot
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1016/s0140-6736(16)00561-4openalex-snapshot
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30496-xopenalex-snapshot
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30065-7openalex-snapshot
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(17)30616-2openalex-snapshot
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
inferredcites →https://doi.org/10.1021/tx00005a001openalex-snapshot
Mammalian synthesis of nitrite, nitrate, nitric oxide, and N-nitrosating agents
inferredcites →https://doi.org/10.1038/nature06244openalex-snapshot
The Human Microbiome Project
inferredcites →https://doi.org/10.1038/nrc3610openalex-snapshot
The microbiome and cancer
inferredcites →https://doi.org/10.1038/nrn3346openalex-snapshot
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
inferredcites →https://doi.org/10.1038/nrurol.2017.16openalex-snapshot
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
inferredcites →https://doi.org/10.1038/s41391-018-0041-1openalex-snapshot
The microbiome in prostate inflammation and prostate cancer
inferredcites →https://doi.org/10.1038/s41391-018-0061-xopenalex-snapshot
Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies
inferredcites →https://doi.org/10.1038/s41598-017-11237-6openalex-snapshot
Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer
inferredcites →https://doi.org/10.1038/s41598-018-29054-wopenalex-snapshot
The urinary microbiome associated with bladder cancer
inferredcites →https://doi.org/10.1056/nejmoa060655openalex-snapshot
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa065044openalex-snapshot
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1510665openalex-snapshot
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1613683openalex-snapshot
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa1816714openalex-snapshot
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1093/aje/kwh014openalex-snapshot
History of Urinary Tract Infection and Risk of Renal Cell Carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdy103openalex-snapshot
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
inferredcites →https://doi.org/10.1093/carcin/bgz008openalex-snapshot
Microbiome signatures in prostate cancer
inferredcites →https://doi.org/10.1097/ju.0000000000000910openalex-snapshot
The Urethral Microbiota: A Missing Link in the Female Urinary Microbiota
inferredcites →https://doi.org/10.1097/mou.0000000000000088openalex-snapshot
New agents for bacillus Calmette–Guérin-refractory nonmuscle invasive bladder cancer
inferredcites →https://doi.org/10.1101/gr.096651.109openalex-snapshot
The NIH Human Microbiome Project
inferredcites →https://doi.org/10.1111/bju.14683openalex-snapshot
Old instillations and new implications for bladder cancer: the urinary microbiome and intravesical BCG
inferredcites →https://doi.org/10.1111/j.1464-410x.2010.09622.xopenalex-snapshot
Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt
inferredcites →https://doi.org/10.1126/science.1195568openalex-snapshot
Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System?
inferredcites →https://doi.org/10.1126/science.1240527openalex-snapshot
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
inferredcites →https://doi.org/10.1126/science.1240537openalex-snapshot
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
inferredcites →https://doi.org/10.1126/science.aad1329openalex-snapshot
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
inferredcites →https://doi.org/10.1126/science.aan3706openalex-snapshot
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
inferredcites →https://doi.org/10.1126/science.aan4236openalex-snapshot
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
inferredcites →https://doi.org/10.1126/science.aao3290openalex-snapshot
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
inferredcites →https://doi.org/10.1128/cmr.12.1.97openalex-snapshot
Relationship between Schistosomiasis and Bladder Cancer
inferredcites →https://doi.org/10.1128/jcm.02876-13openalex-snapshot
Urine Is Not Sterile: Use of Enhanced Urine Culture Techniques To Detect Resident Bacterial Flora in the Adult Female Bladder
inferredcites →https://doi.org/10.1128/jcm.05852-11openalex-snapshot
Evidence of Uncultivated Bacteria in the Adult Female Bladder
inferredcites →https://doi.org/10.1128/microbe.4.393.1openalex-snapshot
NIH Human Microbiome Project
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-0724openalex-snapshot
Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-0960openalex-snapshot
Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation Enteropathy
inferredcites →https://doi.org/10.1177/1933719112466306openalex-snapshot
Adhesion of Lactobacillus iners AB-1 to Human Fibronectin: A Key Mediator for Persistence in the Vagina?
inferredcites →https://doi.org/10.1186/s12864-019-5457-zopenalex-snapshot
Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer
inferredcites →https://doi.org/10.1200/jco.18.02218openalex-snapshot
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
inferredcites →https://doi.org/10.1200/jco.2009.23.9764openalex-snapshot
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2015.63.7421openalex-snapshot
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
inferredcites →https://doi.org/10.1200/jco.2016.67.9761openalex-snapshot
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
inferredcites →https://doi.org/10.1200/jco.2016.71.6795openalex-snapshot
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
inferredcites →https://doi.org/10.1371/journal.pbio.1002533openalex-snapshot
Revised Estimates for the Number of Human and Bacteria Cells in the Body
inferredcites →https://doi.org/10.1371/journal.pntd.0005826openalex-snapshot
The microbiome in urogenital schistosomiasis and induced bladder pathologies
inferredcites →https://doi.org/10.1371/journal.pone.0014116openalex-snapshot
Characteristic Male Urine Microbiomes Associate with Asymptomatic Sexually Transmitted Infection
inferredcites →https://doi.org/10.1373/clinchem.2012.187617openalex-snapshot
The Human Gut Microbiome and Body Metabolism: Implications for Obesity and Diabetes
inferredcites →https://doi.org/10.1586/era.09.29openalex-snapshot
Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma
inferredcites →https://doi.org/10.18632/oncotarget.10547openalex-snapshot
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
inferredcites →https://doi.org/10.21037/atm-20-2976openalex-snapshot
The human microbiome and genitourinary malignancies
inferredcites →https://doi.org/10.21037/hbsn.2018.11.12openalex-snapshot
The role of gut microbiota in immune checkpoint inhibitor therapy
inferredcites →https://doi.org/10.3389/fcimb.2013.00041openalex-snapshot
The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults
inferredcites →https://doi.org/10.3389/fcimb.2018.00167openalex-snapshot
Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China
inferredcites →https://doi.org/10.4161/cbt.7.12.6940openalex-snapshot
Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
inferredcites →https://doi.org/10.6004/jnccn.2019.5008openalex-snapshot
NCCN Guidelines Updates: Management of Metastatic Kidney Cancer.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4182276openalex-extracted
inferred← citeshttps://doi.org/10.1002/imo2.70081openalex-snapshot
Microbiome‐urothelium crosstalk in bladder cancer: From dysbiosis to clinical translation
inferred← citeshttps://doi.org/10.1002/mco2.221openalex-snapshot
Human microbiomes in cancer development and therapy
inferred← citeshttps://doi.org/10.1007/978-3-031-40901-1_11openalex-snapshot
Predictive Biomarkers in Advanced Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s00345-021-03924-xopenalex-snapshot
Uncovering the role of urinary microbiota in urological tumors: a systematic review of literature
inferred← citeshttps://doi.org/10.1007/s00345-024-05173-0openalex-snapshot
A review of urinary bladder microbiome in patients with bladder cancer and its implications in bladder pathogenesis
inferred← citeshttps://doi.org/10.1007/s13402-023-00876-9openalex-snapshot
The microbiota and renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/b978-0-443-30194-0.00031-xopenalex-snapshot
Ayurveda in integrative oncology
inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e17040openalex-snapshot
Urinary Microbiota and Serum Metabolite Analysis in Patients with Diabetic Kidney Disease
inferred← citeshttps://doi.org/10.1016/j.isci.2024.109893openalex-snapshot
Unveiling the intratumoral microbiota within cancer landscapes
inferred← citeshttps://doi.org/10.1016/j.jaim.2022.100676openalex-snapshot
Integrating ayurvedic medicine into cancer research programs part 1: Ayurveda background and applications
inferred← citeshttps://doi.org/10.1016/j.prnil.2022.03.004openalex-snapshot
Prostate diseases and microbiome in the prostate, gut, and urine
inferred← citeshttps://doi.org/10.1016/j.urolonc.2024.07.003openalex-snapshot
The gut microbiome and dietary metabolites in the treatment of renal cell carcinoma
inferred← citeshttps://doi.org/10.1158/2159-8290.cd-21-0324openalex-snapshot
The Cancer Microbiome: Recent Highlights and Knowledge Gaps
inferred← citeshttps://doi.org/10.1177/15330338231164196openalex-snapshot
Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma
inferred← citeshttps://doi.org/10.1186/s11658-024-00538-0openalex-snapshot
Unlocking the secrets: exploring the influence of the aryl hydrocarbon receptor and microbiome on cancer development
inferred← citeshttps://doi.org/10.1186/s12967-025-07355-9openalex-snapshot
Integrative pan-cancer analysis of intratumoral microbial communities for biomarker discovery and diagnostic modeling
inferred← citeshttps://doi.org/10.21608/jsrs.2023.331814openalex-snapshot
Urinary microbiota and lower urinary tract disorders
inferred← citeshttps://doi.org/10.26457/recein.v14i56.2857openalex-snapshot
Implicaciones del microbioma en la etiología y el tratamiento del cáncer de próstata en humanos.
inferred← citeshttps://doi.org/10.32388/j0u1j3openalex-snapshot
Exploring the Dynamic Interplay Between the Human Micro-Biome and Cancer Development, Progress and Therapy
inferred← citeshttps://doi.org/10.33696/cancerimmunol.6.078openalex-snapshot
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers
inferred← citeshttps://doi.org/10.3389/fcimb.2024.1409464openalex-snapshot
The intratumoral microbiota: a new horizon in cancer immunology
inferred← citeshttps://doi.org/10.3389/fcimb.2026.1760700openalex-snapshot
Microbial dysbiosis and inferred functional profiling reveals the potential role of Methylobacterium in prostate cancer
inferred← citeshttps://doi.org/10.3389/fcimb.2026.1890640openalex-snapshot
Urinary microbiota in bladder cancer: insights into pathogenesis, diagnosis, and therapeutic potential
inferred← citeshttps://doi.org/10.3390/biomedicines10081783openalex-snapshot
Bacteria for Treatment: Microbiome in Bladder Cancer
inferred← citeshttps://doi.org/10.3390/cancers15092539openalex-snapshot
Insights into the Human Microbiome and Its Connections with Prostate Cancer
inferred← citeshttps://doi.org/10.3390/cancers16081549openalex-snapshot
Prostate Tissue Microbiome in Patients with Prostate Cancer: A Systematic Review
inferred← citeshttps://doi.org/10.3390/ijms25031732openalex-snapshot
The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer
inferred← citeshttps://doi.org/10.3390/medicina59030483openalex-snapshot
The Association of Prostate Cancer and Urinary Tract Infections: A New Perspective of Prostate Cancer Pathogenesis
inferred← citeshttps://doi.org/10.3390/metabo11110756openalex-snapshot
Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?
inferred← citeshttps://doi.org/10.3892/ijo.2023.5592openalex-snapshot
Effects of gut microbiome and obesity on the development, progression and prevention of cancer (Review)
inferred← citeshttps://doi.org/10.4103/huaj.huaj_3_23openalex-snapshot
Urinary Bladder Microbiome Identification Protocol with Proteomics in Bladder Cancer Patients and Review of the Literature
showing the first 32 of 33
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.